Health ❯ Healthcare

Adverse Effects

Treatment-Emergent Adverse Effects Drug Safety Medication Side Effects Treatment-Related Adverse Effects Cytokine Release Syndrome Gastrointestinal Issues Vaccine Safety Treatment-Related Adverse Events Safety Profiles Vaccine Side Effects Side Effects Myocarditis Clinical Safety Pancreatitis Medication Safety Gastrointestinal Events Medication Risks Clinical Research Overdose Symptoms Hypoglycemia Vaccine Reactions Emergency Room Visits Drug Side Effects Immune-Related Adverse Events Mental Health Gastrointestinal Side Effects Treatment Tolerability Irritation Vaccine-Related Myocarditis Vaccine Adverse Event Reporting System Treatment-related Adverse Effects Toxicity Profiles Medication Tolerance Chemotherapy Drug Toxicity Treatment Emergent Adverse Events Medication Errors Treatment-Related Toxicity Vaccine Efficacy Safety Data Treatment-Related Events Treatment-related Adverse Events Drug Safety Profiles Toxicity Levels Blood Clots Serious Adverse Events Thrombosis Cardiac Complications Temporary Health Consequences Temporary Health Issues Serious Adverse Effects Medical Advice Clinical Outcomes Chronic Toxicity Treatment-Emergent Adverse Events Clinical Trials GI-related Issues Monitoring Temporary Effects Hypersensitivity Pulmonary Infarction Treatment-related Events Radiation Necrosis

FDA Approves Juvmo as First D1/D5 Agonist for Parkinson’s Disease

The drug’s D1/D5 mechanism could slow patients’ need to raise levodopa doses, with U.S. availability scheduled for October 2026.

FDA Approves Isembyld, First Muscle‑Directed Therapy for Spinal Muscular Atrophy

B7‑H3 Antibody‑Drug Conjugates Cut Death Risk by Half in Relapsed Small‑Cell Lung Cancer

Aficamten Improves Symptoms and Exercise Capacity in Nonobstructive HCM

Fauci Diaries Released Show June 2021 Pulmonary Infarction

Lancet Review Finds mRNA Vaccines Safe and Highly Effective

Haleon Recalls Four Lots of Gas‑X Extra Strength Softgels

EU Panel Recommends Braftovi Plus Cetuximab and FOLFOX for First‑Line BRAF‑Mutant Colorectal Cancer

FDA Grants Accelerated Approval to First BCL2 Drug for Relapsed Mantle Cell Lymphoma

FDA Clears All-Oral Decitabine/Cedazuridine Plus Venetoclax for Older AML Patients

FDA Panel Rejects AstraZeneca Breast Cancer Drug, Backs Prostate Therapy

FDA Clears Vepdegestrant, First PROTAC Cancer Drug, for ESR1‑Mutated Breast Cancer

Cadonilimab Plus Chemo Delivers Strong Phase 2 Signal in Frontline Endometrial Cancer

3.1 Million Bottles of Store-Brand Eye Drops Recalled for Sterility Concerns

FDA Approves Nivolumab Plus AVD as First-Line Therapy for Advanced Hodgkin Lymphoma

NEJM Study Identifies Viral Protein and Antibody Mutation Behind Rare Vaccine‑Linked Clots

Moderna–Merck Personalized Melanoma Vaccine Sustains 5-Year Benefit, Cutting Recurrence Risk by 49%

Tucatinib Added to First-Line HER2 Maintenance Prolongs Progression-Free Survival in Phase 3 Trial

Sacituzumab Govitecan Gains First-Line Ground in TNBC, Falls Short in Early HR+/HER2− Use

Roche’s Giredestrant Cuts Early Breast Cancer Recurrence 30% in Phase III Trial